ClinicalTrials.gg
Not yet recruitingNCT06453785IP10-COMPACTUpdated Jun 12, 2024

Comparing pOrtable MRI and TRUS-Fusion Prostate Biopsy to Assess aCcuracy of Prostate Cancer Detection

An interventional study of Promaxo portable MRI in Prostate Cancer, sponsored by Imperial College London. Not yet recruiting at 1 site in United Kingdom. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-12.

Sponsored by Imperial College London · Not applicable, Interventional, and Diagnostic

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
85
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Prostatic Neoplasms by Imperial College London — 4 open to participants now, 6 under way, none of them phase 3. Prostatic Neoplasms · Imperial College London.

Started
2025
the only one that year
No phase
5 of 13
3 open now
Registered
12th of 13
by date

Among the 13 studies in Prostatic Neoplasms by Imperial College London, this one is the only one that started in 2025, is one of 5 with no phase, and was the 12th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

4 of the 13 studies in Prostatic Neoplasms by Imperial College London are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Prostatic Neoplasms by Imperial College London, or all of them as a file.
02

Study summary

Currently, patients suspected of having prostate cancer undergo an MRI followed by targeted biopsies of any suspicious lesions under trans-rectal ultrasound (TRUS) guidance. This pathway is labour, time, and cost-intensive. Additionally, TRUS-MRI-Fusion devices are needed, which overlay the MRI scan onto the TRUS used for biopsies. This can lead to targeting errors due to mismatched images. Although biopsies can be performed in the MRI scanner to reduce these errors, it requires a significant amount of time within an expensive MRI scanner in the radiology department, along with special MRI-compatible equipment. Portable MRI technology has the potential to reduce these errors and streamline the diagnostic pathway to one visit. The Promaxo portable MRI is an FDA-cleared MRI device for MR-guided procedures. It uses a novel "truly" open MRI with an unobstructed field of view and a central aperture for robotic-guided intervention and has a limited footprint, allowing it to be placed in a standard operating theatre or large clinic room. The strength of the magnet is also low enough that special precautions and equipment are not needed to take biopsies.

The intention is to conduct a study that answers the following research question: How does the accuracy of targeted biopsies of the prostate performed under the guidance of a portable MRI scanner compare to TRUS-MRI-fusion biopsies?

Design: A single-arm, single-center IDEAL stage 2a study (n=85 patients) of patients undergoing prostate biopsy for suspected prostate cancer, where each patient would undergo both a portable MRI-registered biopsy and a TRUS-image-fusion biopsy. To reduce the risk of bias between the two modalities, the order of the modality will be randomized 1:1. There will be no blinding of the surgeon.

The primary outcome will be the technical feasibility of performing portable MRI and portable MRI-targeted biopsies and estimates on cancer detection.

Read the detailed description

Design: A single arm, singe centre study of 85 patients who have been selected to undergo prostate biopsy for suspected prostate cancer. Each patient would undergo both a portable MRI registered biopsy and the local standard ultrasound fusion biopsy. To reduce the risk of bias between the two types of biopsy the sequence will be randomised 1:1. There will be no blinding of the surgeon.

Patient Journey:

Patients eligible for the study will have already undergone a standard of care prostate MRI and offered a biopsy for any suspicious lesions seen. Eligible Patients will initially be contacted by a member of the study team and given written information on the study, After a period of time for the patient to review the information the patient will be contacted to give consent which can either be performed remotely or face-to-face.

After consent they will be asked to fill in questionnaires for baseline genito-urinary and bowel function using validated questionnaires and overall health status; this will be online or via paper copies. The questionnaires will consist of the HADS score questionnaire, EPIC (urinary, erectile, bowel) questionnaires and EuroQoL [EQ-5D-5L].

Patients who have consented to the study will then undergo a combined biopsy procedure either under local anaesthetic or if the patient wishes under sedation or general anaesthetic.

The current biopsy standard operating procedure (SOP) requires that 6 targeted cores per-lesion are taken along with 10-12 systematic cores of the remaining prostate. To ensure patient do not have cores taken in excess of the local SOP each enrolled patient will undergo transperineal prostate biopsy under local anaesthetic or sedation/general anaesthetic with a total of 6-targeted cores taken per lesion (three using each biopsy modality, ultrasound fusion or Portable MRI). All suspicious lesions will biopsied.

The patient will then be seen again in either in clinic (remote or face to face) to be given their biopsy results 2-12 weeks after the biopsy. The time point for this appointment will depend on the processing time of the biopsies by the pathology department as per the local standard of care clinical pathway. At this visit patients will be asked again to fill in questionnaires for baseline genito-urinary and bowel function using validated questionnaires and overall health status; this will be online or via paper copies. The questionnaires will consist of the HADS score questionnaire, EPIC (urinary, erectile, bowel) questionnaires and EuroQoL [EQ-5D-5L]. All the above visits mirror the local standard of care clinical pathway and except for the consent visit which could take place on the same day of the biopsy if the patient wishes there will be no additional burden of visits upon the patient.

There will be some optional consent points:

First, patients will also be asked to give optional consent for identifiable data to be linked with the national databases (ONS and HES database). Subsequent funding will be applied for from academic and charity funders to allow to carry out the linkage work. The identifiable fields (NHS number) required for linkage will be encrypted using a one-way encryption algorithm. Patients will be asked if they are happy to give consent for their health status to be followed up over time. This will be done by linking their name and NHS number with records held by the NHS and maintained by the NHS Information Centre and NHS Central Register or any applicable NHS information system.

This will allow to track what happens after the study finishes and observe if anyone gets cancer in future and about the type of cancer and treatment they have had. Patients will be asked whether or not they give permission to be contacted by member of the study research team within 10 years of signing their health status (including details of any other tests and treatment they have had since the study) and quality of life. If the patient decides to take part a member of the study research team may send this request to the patient's home address. The intention is to link individual trial informationto national databases on cancer diagnosis, GP databases on healthcare and medication use and finally death registry to see if any of the men died from prostate cancer.

As prostate cancer is often a slow-growing disease which may not progress for many years, patients will also be asked if they are happy to keep personal data stored or accessed for 10 years on the NHSCR (National Health Service Care Register). Second, in order to get an area based estimate of deprivation, the participants' partial postcodes will be converted into an Index of Multiple Deprivation (IMD) score. The IMD is the established index of deprivation for England and Wales and has been adopted widely in studies across local and national government. Partial postcodes will be stored in the study database, only IMD rank, which is based on detailed ward-level index of deprivation based on severe separate domains.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • biopsy
  • MRI
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or above (no upper limit)
  • Raised age specific PSA
  • LIKERT/PIRADS 3 or above lesion on prostate mpMRI who have been advised to undergo a prostate .

Exclusion criteria

Exclusion Criteria:

  • Patients who are unable to undergo a diagnostic standard of care MRI due to metallic implants, foreign body or devices.
  • Patients with a Cardiac pacemaker or Implantable cardioverter-defibrillator (ICD).
  • to performing a guided by a transrectal ultrasound probe
  • Unable to give to the study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
85 participants (estimated)

Study arms

  • Other
    Patients with suspected prostate cancer

    Patients who undergo prostate biopsy for suspected prostate cancer. Each patient would undergo both a portable MRI-registered biopsy and a TRUS-image-fusion biopsy. To reduce the risk of bias between the two modalities, the order of the modality will be randomized 1:1. There will be no blinding of the surgeon.

    Device: Promaxo portable MRI

Interventions

  • DevicePromaxo portable MRI

    The Promaxo portable MRI is an FDA cleared MRI device for MR-guided procedures. It uses a novel "truly" open MRI with an unobstructed field of view and central aperture for robotic guided intervention and has a limited footprint allowing it to be places in a standard operating theatre or large clinic room. The strength of magnet is also low enough that special precautions and equipment are not to take biopsies.

06

What researchers measure

Primary outcomes

  1. Percentage of Clinicical Significance of Cancer Detected

    The proportion of patients with biopsy cores that yield cancer-positive results and the concordance between MRI-guided biopsy results and histopathological findings.

    Time frame: 2 years

  2. Technical feasibility of performing portable MRI and portable MRI targeted biopsies.

    Percentage of biopsy completed

    Time frame: 2 years

Secondary outcomes

  1. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

    The Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 is a standardized system for grading the severity of adverse events (AEs) in clinical trials and medical practice. In CTCAE v4.0, adverse events are graded on a scale from Grade 1 to Grade 5, with each grade indicating increasing severity: Grade 1: Mild AE Grade 2: Moderate AE Grade 3: Severe or medically significant but not immediately life-threatening AE Grade 4: Life-threatening consequences AE Grade 5: Death related to AE

    Time frame: 2 years

  2. Patient reported outcome measures (PROMS / HADS-D) of genitourinary health

    Hospital Anxiety and Depression Scale (HADS): Consists of 14 items, seven for anxiety (HADS-A) and seven for depression (HADS-D), scored on a Likert scale from 0 to 3. Higher scores indicate more anxiety or depression. Clinically significant levels are defined by cutoff scores.

    Time frame: 2 years

  3. Overall health-related quality of life as assessed by ICIQ-UI short form

    The International Consultation on Incontinence Questionnaire Urinary Incontinence Short Form (ICIQ-UI SF) is a validated questionnaire used to assess the impact of urinary incontinence on an individual's health-related quality of life (HRQoL). It specifically focuses on the experience of urinary incontinence, including its frequency, severity, and the degree to which it affects daily activities and emotional well-being. The total score can be used to classify the severity of urinary incontinence: 0-5: Slight or no impact 6-12: Moderate impact 13-18: Severe impact 19-21: Very severe impact

    Time frame: 2 years

  4. Overall health-related quality of life as assessed by IPSS

    The International Prostate Symptom Score (IPSS) provides a quantitative measure of urinary symptoms, helping clinicians evaluate symptom severity and monitor changes over time.ach question in the IPSS is scored on a Likert scale from 0 to 5, with higher scores indicating greater symptom severity. The total IPSS score is calculated by summing the scores for the individual questions, resulting in a total score ranging from 0 to 35. Mild: 0-7 Moderate: 8-19 Severe: 20-35

    Time frame: 2 years

  5. Overall health-related quality of life as assessed by IPSS-QoL

    International Prostate Symptom Score-Quality of Life assesses the impact of lower urinary tract symptoms (LUTS) on a patient's quality of life (QoL) specifically related to urinary symptoms associated with benign prostatic hyperplasia (BPH) or prostate enlargement. The IPSS-QoL consists of a single question that asks the patient to rate their perception of how urinary symptoms have affected their quality of life during the past month. The question is scored on a Likert scale from 0 to 6, with the following response options: Delighted (scored as 0) Pleased (scored as 1) Mostly satisfied (scored as 2) Mixed (about equally satisfied and dissatisfied) (scored as 3) Mostly dissatisfied (scored as 4) Unhappy (scored as 5) Terrible (scored as 6)

    Time frame: 2 years

  6. Overall health-related quality of life as assessed by EQ5D

    EuroQol 5-Dimension (EQ-5D) assesses overall health status. Its questionnaire has two components: Descriptive System evaluates health across five dimensions: Mobility, Self-care, Usual activities, Pain/discomfort, and Anxiety/depression, each with three severity levels. This yields 243 possible health states. Visual Analog Scale (VAS) rates overall health from 0 (worst imaginable) to 100 (best imaginable).

    Time frame: 2 years

  7. The sensitivity, specificity, and accuracy of using portable MRI to detect clinically significant prostate cancer

    Detection of clinically significant prostate cancer defined as Gleason grade 3+4 or greater and/or a maximum cancer core length of \>/= 4mm. Detection of clinically significant prostate cancer defined as Gleason grade 4+3 or greater and/or a maximum cancer core length of \>/= 6mm. This outcome will measure the sensitivity, specificity, and accuracy of portable MRI in detecting prostate cancer deemed clinically significant. Sensitivity refers to the proportion of true positive cases detected by the portable MRI, while specificity refers to the proportion of true negative cases correctly identified as negative. Accuracy measures the overall correctness of the portable MRI's detection compared to a standard MRI, or histopathology from biopsy samples.

    Time frame: 2 years

  8. Concordance Rate of Prostate Cancer Detection between Portable MRI and Standard mpMRI

    A matched cohort of mpMRI, portable MRI, targeted and systematic biopsies will be created to estimate concordance of portable MRI compared to mpMRI in the detection of clinically significant cancer. Data from this analysis will allow the development of much larger RCT and screening study.

    Time frame: 2 years

  9. Patient reported outcome measures (PROMS / EPIC) of genitourinary health

    EPIC (urinary, erectile, bowel): Expanded Prostate Cancer Index Composite. The score range is usually from 0 to 100. Higher scores denote better function and quality of life in respective domains.

    Time frame: 2 years

  10. Patient reported outcome measures (PROMS / EuroQol) of genitourinary health

    EuroQol (EQ-5D-5L): EuroQol 5-Dimension 5-Level Scale. Assessing mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Responses range from no problems to extreme problems. VAS ranges from 0 to 100, reflecting worst to best imaginable health.

    Time frame: 2 years

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2025; primary completion for Apr 2027, 25 months later.

Of 1,104 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 25 months is below that.

Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2024
First posted
Jun 12, 2024
StartEst.
Mar 2025
Primary completionEst.
Apr 2027
CompletionEst.
Jul 2027
Last update
Jun 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06453785
Responsible party
Sponsor
First posted
Jun 12, 2024
Start date
Mar 2025 (estimated)
Primary completion
Apr 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Jun 12, 2024

Study contacts

Taimur Shah, Dr
Contact
t.shah@imperial.ac.uk
020 3311 6611
Taimur Shah, Dr
principal investigator · Imperial College London

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion